120 likes | 340 Views
Slender Medical. Ultrasound Without Limits. Introduction. Founded 2007. Headquarters – Herzliya, Israel Technology: Non-invasive excess-fat removal using high intensity focused ultrasound Market: Aesthetic market, clinics of plastic surgeons and dermatologists, medical SPAs
E N D
Slender Medical Ultrasound Without Limits
Introduction • Founded 2007. Headquarters – Herzliya, Israel • Technology: Non-invasive excess-fat removal using high intensity focused ultrasound • Market: Aesthetic market, clinics of plastic surgeons and dermatologists, medical SPAs • Large market opportunity: $8 B • Launch in 2010 • Exciting near term exit prospect • Experienced, multi-disciplinary team • Strong IP • Developmental phase: Preclinical phase Confidential
Chin Liposuction Before After Results obtained by standard liposuction Confidential
Large Market Opportunity • Up to 80% of all women over the age of 20 struggle with excess fat • 495,000 potential professional users WW (source: M. Moretti, Medical Insights Inc.) • 45,000 dermatologists, plastic surgeons • (150,000 SPA, paramedical) • 300,000 other physician specialties (15%) • Estimated end user price $90,000 • Total market opportunity: $8 B (Only for the capital part. Consumables will create additional revenue) Confidential
Surgical vs. Nonsurgical Procedures Liposuction total expenditure:$1.4 B American Society for Aesthetic Plastic Surgery, 2007 Confidential
Product • Ultrasonic elements applied to the treated area • Focused ultrasound for breaking down adipose tissue • Through transmission ultrasound for monitoring the treatment process • Treatment and monitoring are performed in a closed loop • Ultrasonic transmission is performed parallel to the skin. • Optional several sizes of hand held probe • Short time to market (Launch in 2010) Confidential
Technology Benefits • Skin parallel transmission. Safer • avoiding bone pain • preventing transmission of acoustic energy to internal organs • Ability to treat organs that cannot be treated by the competitors (chin and arms) • Temperature feedback. Higher efficacy & Safer • Tissue (muscle/fat) differentiation. Safer • Several probe designs allowing treatment of both large and small areas such as chin and arms. More treatment opportunities for the physician Confidential
Team • Dr. Liat Tsoref, Founder and CEO EarlySense – Director of BD; Sunlight Medical (bone assessment ultrasound)- VP R&D; PhD in Physics, TAU • Prof. Haim Azhari, Founder and CTA Researcher in the Technion • Mr. Gregory Krasnov, R&D Eng. MSc,Ultrasound specialist, JetGuide Ltd., Technion • Yossi Gross, Founder and Consultant Serial entrepreneur (VisionCare, BioControl, TransPharma, BrainsGate, Beta-O2 etc.) • Dr. Amiram Borenstein, Consultant MD, MSc, Plastic and Aesthetic Surgeon Confidential
Objective - Investment • Investment to date: Rainbow Medical Ltd: $ 1,000,000 • "A" Round Target $ 2M • A-Round UOP • Clinical study, phase I and II • Development of a beta prototype • CE clearance Confidential
Summary • Body shaping is a promising market with very high growth potential • Short time to market – LAUNCH in 2010 • Multidisciplinary team with many years of experience in the field of ultrasound • A unique and proprietary technology • The combination of focused ultrasound treatment and monitoring abilities will turn Slender Medical into a leader in the body shaping market Confidential